Abstract:Background: Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare and progressive disease caused by mutations in the TYMP gene, which encodes the enzyme thymidine phosphorylase (TP). This results in a systemic accumulation of nucleosides and mitochondrial toxicity. AAV-based liver-directed gene therapy has shown efficacy in preclinical studies, but it has limitations such as a decline of transgene expression long-term. We propose that gene editing can circumvent some of these problems.Methods: We performed a preclinical study in the murine model of MNGIE to assess that the coordinated delivery of CRISPR/Cas9 and a TYMP cDNA caused the efficient integration of a TYMP transgene into introns of the Tymp and Alb loci in hepatocytes. CRISPR/Cas9 was delivered either as mRNA using nanoparticles or in AAV2/8 viral vectors; the latter were also used to package the TYMP cDNA. We assessed the efficient integration of the templates into the liver cells, and monitored the nucleoside levels in plasma to detect the biochemical correction.Findings: The best results were obtained using lipid nanoparticles. The consistent and stable nucleoside reduction observed correlated with the presence of TYMP mRNA and functional enzyme in the liver cells. In mice with an edited Alb locus, the transgene produced a hybrid Alb-hTP protein that was secreted, with high levels of TP activity in plasma.Interpretation: Liver-directed gene editing is a feasible approach to achieve the long-term biochemical correction of the disease, with several advantages over previous methods.Funding Information: This project was made possible with financial support from the Instituto de Salud Carlos III/FEDER (grant PI15/00172) and from MINECO/FEDER (grant RTI2018-094734-B-C22). The support of the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) of the Generalitat de Catalunya, through SGR 2017 1559 grant, is also acknowledged.Declaration of Interests: S.H.Y.F. and Y.K.T. are employees of Acuitas Therapeutics, a company focused on the development of lipid nanoparticle delivery systems for nucleic-acid-based drugs. RM was the recipient of personal fees associated with advisory tasks and of financial support from Modis Therapeutics for research outside the submitted work. RM also holds a patent “Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes” (PCT/US16/038110), with royalties paid to Modis Therapeutics.INCOMPLETEEthics Approval Statement: All animal procedures were performed in accordance with European recommendations and were approved by our institutional ethics committee (Comitè Ètic d’Experimentació Animal).

Adapting CRISPR/Cas9 System for Targeting Mitochondrial Genome

Direct Evidence of CRISPR-Cas9-mediated Mitochondrial Genome Editing

Abstract P23: Mitochondrial Delivery of Functional Nucleic Acids for Targeting of Mitochondrial Dysfunction

Research Progress in Mitochondrial Gene Editing Technology.

Interrogating Mitochondrial Biology and Disease Using CRISPR/Cas9 Gene Editing

Targeted deletions in human mitochondrial DNA engineered by Type V CRISPR-Cas12a system

CRISPR/Cas9-mediated base editors and their prospects for mitochondrial genome engineering

Strand-selective base editing of human mitochondrial DNA using mitoBEs

Tools for editing the mammalian mitochondrial genome

CRISPR/Cas9-mediated Mutagenesis at Microhomologous Regions of Human Mitochondrial Genome.

A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing

Mitochondrial genome editing: strategies, challenges, and applications

An Episomal CRISPR/Cas12a System for Mediating Efficient Gene Editing

Applications of Gene Editing in Mitochondrial Diseases

Selective Elimination of Mitochondrial Mutations in the Germline by Genome Editing

Enzymatic tools for mitochondrial genome manipulation

Engineered mitochondrial A-to-G editors with enhanced efficiency and targeting scope

CRISPR-free, strand-selective mitochondrial DNA base editing using a nickase

Harnessing accurate mitochondrial DNA base editing mediated by DdCBEs in a predictable manner

New potentials of mitochondrial DNA editing

Preclinical Assessment of a Gene Editing Approach in a Mouse Model of MNGIE